Vaccines - Singapore

  • Singapore
  • In Singapore, the revenue in the Vaccines market is forecasted to reach US$97.50m by 2024.
  • This market is expected to exhibit an annual growth rate (CAGR 2024-2029) of 8.29%, leading to a market volume of US$145.20m by 2029.
  • When compared globally, United States is anticipated to generate the highest revenue in the Vaccines market, amounting to US$29,120.00m in 2024.
  • Singapore's robust healthcare system and strategic partnerships with global pharmaceutical companies position it as a leading hub for vaccine research and development in Southeast Asia.

Key regions: Australia, Italy, France, South Korea, Brazil

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The demand for vaccines in Singapore has been on the rise in recent years due to various factors such as increased awareness of the importance of vaccination, government initiatives to promote immunization, and the growing elderly population.

Customer preferences:
Singaporeans have shown a growing preference for vaccines that offer protection against multiple diseases, such as the combination vaccines that protect against measles, mumps, and rubella. In addition, there is a growing demand for vaccines that offer long-term protection and require fewer doses.

Trends in the market:
The vaccines market in Singapore has been experiencing a shift towards a more preventive approach to healthcare. This has resulted in an increased demand for vaccines that not only prevent infectious diseases but also chronic diseases such as cancer. There is also a growing trend towards personalized vaccines that are tailored to an individual's genetic makeup.

Local special circumstances:
Singapore has a highly developed healthcare system and a strong focus on disease prevention. The government has implemented various initiatives to promote immunization, such as the National Childhood Immunisation Schedule and the National Adult Immunisation Schedule. In addition, Singapore has a large elderly population, which has contributed to the growing demand for vaccines that protect against diseases that are more common in older age groups.

Underlying macroeconomic factors:
Singapore has a high-income economy, which has resulted in a population that is able to afford healthcare services, including vaccines. In addition, Singapore's strategic location and strong infrastructure have made it an attractive market for vaccine manufacturers. The government has also implemented policies to promote the growth of the pharmaceutical industry, which has contributed to the development of the vaccines market in Singapore.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)